ATOSSA THERAPEUTICS, INC. — Director's Dealing 2012

Nov 7, 2012

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ATOSSA GENETICS INC (ATOS)
CIK: 0001488039
Period of Report: 2012-11-07

Reporting Person: QUAY STEVEN C (Director, CEO, 10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	584543	Direct
Common Stock	4275580	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$2.64	2015-07-22	Common Stock (250000)		Direct

Footnotes

F1: Ensisheim Partners, LLC is wholly owned by the Reporting Person and Dr. Shu-Chih Chen, the Chief Scientific Officer of the Company. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of all such securities for purposes of Section 16 or any other purpose.

F2: On July 22, 2010, the Board of Directors approved a grant to the Reporting Person of stock options to purchase an aggregate of 250,000 shares of Common Stock. The first 62,500 options vested on December 31, 2010 with the remaining options to vest in equal quarterly amounts thereafter for three years, assuming continuous and uninterrupted service with the Company.